Search results for "Riba"

showing 10 items of 371 documents

An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C.

2014

none 29 no Background: Aim was to select naïve patients with genotype 1 chronic hepatitis C having a high probability of response to Peg-interferon. +. ribavirin therapy. Methods: In 1073 patients (derivation cohort), predictors of rapid and sustained virological response were identified by logistic analysis; regression coefficients were used to generate prediction models for sustained virological response. Probabilities at baseline and treatment week 4 were utilized to develop a decision rule to select patients with high likelihood of response. The model was then validated in 423 patients (validation cohort). Results: In the derivation cohort, 257 achieved rapid virological response and 8…

OncologyMaleHepacivirusPredictive Value of Testchronic hepatitis C; prediction model of response; peginterferon plus ribavirin dual therapyHepacivirusPolyethylene GlycolPolyethylene Glycolschemistry.chemical_compoundGenotypeViralChronicRapid virological responseDrug CarrierChronic hepatitisSettore MED/12 - GastroenterologiaDrug CarriersbiologyGastroenterologyRecombinant ProteinMiddle AgedViral LoadPrognosisHepatitis CRecombinant ProteinsHCV infectionTreatment OutcomePredictive value of testsCombinationRNA ViralDrug Therapy CombinationFemaleChronic hepatitis; HCV infection; Peg-interferon and ribavirin treatment; Predictors of sustained virological response rapid virological response; Adult; Antiviral Agents; Drug Carriers; Drug Therapy Combination; Female; Genotype; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Prognosis; RNA Viral; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Hepatology; GastroenterologyViral loadHumanAdultmedicine.medical_specialtyGenotypePrognosiAlpha interferonPredictors of sustained virological response rapid virological responseReal-Time Polymerase Chain ReactionAntiviral AgentsDrug TherapyPredictive Value of TestsInternal medicinePredictors of sustained virological responseLinear regressionRibavirinmedicinechronic hepatitis CHumansAntiviral AgentHCV infection; Predictors of sustained virological response Rapid virological response; Peg-interferon and ribavirin treatment; Chronic hepatitisHepaciviruHepatologybusiness.industryRibavirinInterferon-alphaHepatologyHepatitis C Chronicbiology.organism_classificationchemistryImmunologyChronic hepatitiRNAprediction model of responsepeginterferon plus ribavirin dual therapybusinessPeg-interferon and ribavirin treatmentDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

The impact of antiviral treatments on the course of chronic hepatitis C: an evidence-based approach.

2004

Hepatitis C virus chronic infection is currently the most common cause of end-stage liver disease. The benefit of antiviral therapy on liver histology and its impact on the long-term course of the disease has been extensively studied. However, the results are still equivocal and the overall assessment of treatment effect remains difficult to evaluate. Although the conclusions of the last National Institute of Health Consensus Development Conferences on Hepatitis C have recently been published, several important issues still remain unanswered. We review the available data by an evidence-based approach and conclude that: 1) peginterferon alfa is more effective than conventional interferon in …

Oncologymedicine.medical_specialtyCirrhosisCarcinoma HepatocellularHepatitis C virusDiseasemedicine.disease_causeAntiviral AgentsLiver diseasechemistry.chemical_compoundMaintenance therapyPegylated interferonInternal medicineDrug DiscoverymedicineHumansViral hepatitis CRandomized Controlled Trials as TopicPharmacologyEvidence-Based Medicinebusiness.industryRibavirinLiver NeoplasmsHistological benefitHepatitis CHepatitis C Chronicmedicine.diseaseLong-term outcomeTreatment OutcomechemistryCombination treatmentImmunologybusinessPegylated interferonmedicine.drugCurrent pharmaceutical design
researchProduct

Pegylated interferon therapy in chronic hepatitis C: lights and shadows of an innovative treatment

2007

Abstract Pegylated interferon (PEG-IFN) in combination with ribavirin is the standard of treatment for chronic hepatitis C. Several viral and host factors influence the outcome of treatment, such as hepatitis C virus (HCV) genotype, baseline viral load, viral kinetics, race, body weight, advanced liver disease, HIV co-infection, and adherence to therapy. Monitoring the response of HCV to treatment during the early time points (4 weeks or 12 weeks) after initiation of therapy has emerged as a critical tool to predict sustained virologic response (SVR), defined as undetectable serum HCV RNA 24 weeks after the end of therapy. To counterbalance the influence of host and viral factors, treatment…

Oncologymedicine.medical_specialtyHepatitis C virusHuman leukocyte antigenInterferon alpha-2medicine.disease_causeAntiviral AgentsPolyethylene GlycolsLiver diseasechemistry.chemical_compoundChronic hepatitisPegylated interferonInternal medicineRibavirinmedicineHumansHepatologybusiness.industryRibavirinGastroenterologyInterferon-alphavirus diseasesDrug ToleranceHepatitis C Chronicmedicine.diseaseRecombinant ProteinsBlack or African AmericanTreatment OutcomechemistryVirologic responseImmunologybusinessViral loadmedicine.drugDigestive and Liver Disease
researchProduct

Triple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association…

2013

AbstractThe first-generation Protease Inhibitors Boceprevir and Telaprevir administered in triple therapy regimens with Peg-interferon alpha and Ribavirin have been proven effective in increasing the rate of Sustained Virological Response in both naive and treatment-experienced patients with chronic genotype-1 hepatitis C. However, at the individual level, the therapeutic advantage of triple therapy is highly variable and results from the combination of multiple factors related to the characteristics of patient, viral status and liver disease.The recommendations presented are promoted by the Italian Association for the Study of the Liver, with the aim to help the physician in the decision-m…

Oncologymedicine.medical_specialtyProlinePegylated-interferonAlpha interferonHepacivirusPharmacologyAntiviral AgentsTelaprevirTelaprevirPolyethylene GlycolsHCV THERAPYchemistry.chemical_compoundLiver diseaseDrug TherapyPegylated interferonBoceprevirInternal medicineRibavirinmedicineHumansProtease InhibitorsChronicBoceprevir; Cirrhosis; Hepatitis C; Pegylated-interferon; Ribavirin; Telaprevir; Antiviral Agents; Drug Carriers; Drug Therapy Combination; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin; Gastroenterology; HepatologyBoceprevirDrug CarriersHepatologybusiness.industryRibavirinGastroenterologyInterferon-alphaHepatitis CHepatologyHepatitis C Chronicmedicine.diseaseHepatitis CCirrhosischemistryCombinationDrug Therapy CombinationbusinessOligopeptidesmedicine.drug
researchProduct

Therapeutic algorithms for chronic hepatitis C in the DAA era during the current economic crisis: whom to treat? How to treat? When to treat?

2012

The advent of triple therapy (TT) with first-generation protease inhibitors boceprevir (BOC) and telaprevir (TVR) in addition to pegylated interferon and ribavirin resulted in a significant gain in terms of sustained virological response (SVR) when treating naive or previous treated patients with genotype 1 (G1) chronic hepatitis C (CHC). This gain is partly balanced by the increased complexity of treatment and by the raised costs and risks of therapy, making necessary to optimize the indication to TT. Specifically, the identification of patient needing to TT over DT, the choice of the more correct therapeutic approach according to baseline and on treatment SVR predictors, and the timing of…

Oncologymedicine.medical_specialtyReviewPharmacologyAntiviral AgentsTelaprevirVirological responsechemistry.chemical_compoundMedical microbiologyChronic hepatitisPegylated interferonInternal medicineBoceprevirmedicineHumansbusiness.industryRibavirinHepatitis C ChronicDAA HCVEconomic RecessionInfectious DiseaseschemistryPractice Guidelines as TopicDrug Therapy CombinationbusinessAlgorithmsmedicine.drug
researchProduct

Bruņērču (Acari: Oribatida) dzimtu sastāvs un ietekmējošie faktori mājputnu ganību augsnēs bijušā kolhoza "Valmiera" teritorijā

2021

Ar mājputnu ganību izveidi tiek ietekmēti zālāji, un augsnē dzīvojošās bruņērces (Oribatida), kuras ietekmē mājputnu ganību raksturojošie vides faktori - nomīdīšana, putnu mēsli, apkārtējās faunas un floras maiņa, u.tml. Mainoties vides faktoriem zālājos, tiek ietekmētas bruņērču sabiedrības, to dažādu dzimtu sastopamība, sastāvs un indivīdu blīvums. Darba mērķis bija raksturot mājputnu ganību dažādas intensitātes ietekmi uz bruņērču dzimtu sadalījumu un dominējošām dzimtu grupām antropogēni noslogotās augsnēs bijušā kolhoza “Valmiera” teritorijā. Bakalaura darba ietvarā tika ievākti un pētīti augsnes paraugi bijušā kolhoza “Valmiera” teritorijas augsnēs, tā atrodas netālu no Valmieras pils…

OribatidaMājputnu ganībasBioloģijaDzimtu sastāvsDominance
researchProduct

Kontrolētas dedzināšanas ietekme uz augsnes bruņērču (Acari:Oribatida) sugu sabiedrībām priežu mētrājā, aizsargājamo ainavu apvidū "Ādaži"

2018

Bruņērces līdz šim ir maz izmantotas sukcesiju pētījumos un zināšanas par augsnes faunas un bruņērču atbildes reakcijām uz dažādiem traucējumiem ir ierobežotas, taču to relatīvi lēnais dzīves cikls un plašā izplatība tās padara par efektīviem ilgtermiņa bioindikatoriem, kas var liecināt par degšanas ietekmes smagumu. Darba mērķis ir noskaidrot kontrolētas dedzināšanas ietekmi uz augsnes bruņērču sabiedrībām, zemsedzi un augsnes parametriem priežu mētrājā. Augsnes paraugi ievākti pirms un 16 dienas pēc kontrolētas dedzināšanas. Pēc degšanas bruņērču indivīdu skaits samazinājies par 93% un sugu skaits par 77%. Izmaiņas ietekmē degšanas ietekmes smagums. Pēc traucējuma eudominējošs taksons ir …

Oribatidadegšanas ietekmes smagumsdegšanaaugsnes parametriBioloģijamezofauna
researchProduct

Two new species of oribatid mites of Lasiobelba (Acari, Oribatida, Oppiidae) from Nepal, including a key to all species of the genus

2014

Two new species of oribatid mites of the genus Lasiobelba (Oribatida, Oppiidae), Lasiobelba (Lasiobelba) daamsae sp. n. and Lasiobelba (Antennoppia) nepalica sp. n., are described from eastern Nepal. Lasiobelba (L.) daamsae sp. n. is most similar to L. (L.) remota Aoki, 1959 and L. (L.) gibbosa (Mahunka, 1985), however, it differs from both by the anterior part of pedotecta I specifically curved, rostrum pointed and exobothridial setae not shorter than bothridial setae. Lasiobelba (Antennoppia) nepalica sp. n. is most similar to L. (A.) granulata (Mahunka, 1986), however, it differs from the latter by the larger body size, exobothridial setae longer than rostral setae and bothridial setae n…

Oribatidanew speciesbiologyLasiobelbaRostrumIdentification keyZoologySetaBody sizeOribatid mitesbiology.organism_classificationkeyNepalGenusBotanylcsh:ZoologyKey (lock)AnimaliaAnimal Science and ZoologyAcarilcsh:QL1-991OribatidaOppiidaeEcology Evolution Behavior and SystematicsResearch Article
researchProduct

New species of oribatid mites of the genera Lepidozetes and Scutozetes (Acari, Oribatida, Tegoribatidae) from Nepal

2013

Two new species of oribatid mites, Lepidozetes acutirostrum sp. n. and Scutozetes clavatosensillus sp. n., are described from Nepal. The genera Lepidozetes and Scutozetes are recorded for the first time for the Oriental region. The identification keys to the known species of these genera are provided.

Oribatidanew speciesbiologyZoologyTegoribatidaebiology.organism_classificationArticleLepidozetesScutozetesScutozetesLepidozeteskeyNepallcsh:ZoologyKey (lock)descriptionAnimal Science and ZoologyAcarilcsh:QL1-991OribatidaEcology Evolution Behavior and Systematics
researchProduct

The genus Galumna in Nepalese oribatid mite fauna, with notes on systematic placement of some species (Acari, Oribatida, Galumnidae)

2014

The oribatid mite genus Galumna (Oribatida, Galumnidae) is recorded for the first time in Nepal. A new species, Galumna tetraporosa sp. n., is described from soil of secondary mixed broadleaved forest. It is most similar morphologically to G. tokyoensis Aoki, 1966 and G. valida Aoki, 1994, however, it differs from both by the absence of interlamellar setae and the presence of two pairs of notogastral porose areas Aa. Galumna granalata Aoki, 1984 is redescribed on the basis of specimens from Nepal. Galumna floridae (Jacot, 1929) and G. hexagona Balogh, 1960 are transferred to the genus Notogalumna; G. mauritii Mahunka, 1978 is transferred to the genus Dimidiogalumna.

Oribatidanew speciesbiologynew combinationDimidiogalumnaFaunaSetaZoologyNotogalumnabiology.organism_classificationsupplementary descriptionGalumnaGalumnidaeNepalGenusBotanylcsh:ZoologyMiteAnimaliaAnimal Science and ZoologyAcarilcsh:QL1-991OribatidaEcology Evolution Behavior and SystematicsResearch ArticleZooKeys
researchProduct